VIP Road CA CPE Study Circle of EIRC OF ICAI
VIP Road CA CPE Study Circle of EIRC OF ICAI
  • 160
  • 178 158
Group Discussion on Rajiv Bansal (3.10.2024) – I-T Reassessment under Section 148-CA S K Pransukhka
VIPCA Virtual Group Discussion on Rajiv Bansal (3.10.2024) - I-T Reassessment under Section 148-CA S K Pransukhka, Former Member of ITAT
มุมมอง: 455

วีดีโอ

VIPCA 23 24
มุมมอง 685 หลายเดือนก่อน
VIPCA 23 24
Boosting Practice Through LinkedIn by Sanghamitra Dhar
มุมมอง 386 หลายเดือนก่อน
VIPCA Digital Pathshala - Season 2
Intranet for Office, Digital Assets & Training Material for Manpower CA Rahul Rungta
มุมมอง 466 หลายเดือนก่อน
VIPCA Digital Pathshala - Season 2:Rahul Rungta
Practice Automation & Collaborative Working- CA Sumit Bihani
มุมมอง 976 หลายเดือนก่อน
Practice Automation & Collaborative Working by CA Sumit Bihani, Partner at MBRM & Associates
Leaders’ Perspective- From Vision to Victory
มุมมอง 888 หลายเดือนก่อน
VIPCA 16th Annual Conference 2024, CA Deepak Kumar Kedia (IRS), CA Anand Mohan Bajaj
Capital Market Shri Vijay Kedia
มุมมอง 24K8 หลายเดือนก่อน
VIPCA 16th Annual Conference #nse #bse #capitalmarkets #vijaykedia
GST Litigation- CA Dr. Arpit Haldia, Shri Manoj Kumar Kedia,IRS & CA Sushil Kumar Goel
มุมมอง 5198 หลายเดือนก่อน
GST Litigation- CA Dr. Arpit Haldia, Shri Manoj Kumar Kedia,IRS & CA Sushil Kumar Goel
Taxation of Joint Development Agreements & Real Estate
มุมมอง 1768 หลายเดือนก่อน
VIPCA 16th Annual Conference-JDA & Real Estate- CA (Dr.) Girish Ahuja
VIPCA 16th Annual Conference-Inaugural Session
มุมมอง 628 หลายเดือนก่อน
Inaugural Session of VIPCA 16th Annual Conference #icai #CARanjitAgarwal #VIPCA
Critical Analysis of Search and Seizure in the New ERA- CA Dr Girish Ahuja
มุมมอง 1.4Kปีที่แล้ว
Critical Analysis of Search and Seizure in the New ERA- CA Dr Girish Ahuja
Wealth Creation with Capital Market- VIPCA 15th Annual Conference
มุมมอง 375ปีที่แล้ว
Shri Ajay Bagga #Shri S P Tulsian #CA Rakesh Somani #Eureka
VIPCA 15th Annual Conference-Busy Accounting Software
มุมมอง 43ปีที่แล้ว
VIPCA 15th Annual Conference-Busy Accounting Software
Past, Present and Future of GST Litigation- CA Umesh Sharma CA Sushil Goel
มุมมอง 221ปีที่แล้ว
Past, Present and Future of GST Litigation- CA Umesh Sharma CA Sushil Goel
VIPCA 15th Annual Conference- Inaugural Session
มุมมอง 25ปีที่แล้ว
VIPCA 15th Annual Conference- Inaugural Session
Audit Auditors and Technology- CA Anand Prakash Jangid
มุมมอง 223ปีที่แล้ว
Audit Auditors and Technology- CA Anand Prakash Jangid
VIP Road Chartered Accountants' Annual Conference at Kolkata on 18th March 2023,Silver Jubilee Year
มุมมอง 104ปีที่แล้ว
VIP Road Chartered Accountants' Annual Conference at Kolkata on 18th March 2023,Silver Jubilee Year
VIPCA Digital Pathshala - Day 4
มุมมอง 117ปีที่แล้ว
VIPCA Digital Pathshala - Day 4
VIPCA Digital Pathshala - Day 3
มุมมอง 79ปีที่แล้ว
VIPCA Digital Pathshala - Day 3
Code of Ethics (Including NOCLAR) by #Padmashree Crasto
มุมมอง 79ปีที่แล้ว
Code of Ethics (Including NOCLAR) by #Padmashree Crasto
Start Up to Capital Market-Wealth Multiplier-2-Panel Discussion : - Vision 2025 and 2030
มุมมอง 7Kปีที่แล้ว
Start Up to Capital Market-Wealth Multiplier-2-Panel Discussion : - Vision 2025 and 2030
Start Up to Capital Market - Wealth Multiplier-2-The journey of a Unicorn
มุมมอง 318ปีที่แล้ว
Start Up to Capital Market - Wealth Multiplier-2-The journey of a Unicorn
Start Up to Capital Market - Wealth Multiplier-2-Navigating the Landscape of Capital Market
มุมมอง 815ปีที่แล้ว
Start Up to Capital Market - Wealth Multiplier-2-Navigating the Landscape of Capital Market
Start Up to Capital Market -Wealth Multiplier-2-India- The preferred destination for Start-ups
มุมมอง 201ปีที่แล้ว
Start Up to Capital Market -Wealth Multiplier-2-India- The preferred destination for Start-ups
Start Up to Capital Market - Wealth Multiplier-2-Investing for Wealth Creation
มุมมอง 51Kปีที่แล้ว
Start Up to Capital Market - Wealth Multiplier-2-Investing for Wealth Creation
Start Up 2 Capital Market-Wealth Multiplier -2 Session1-Start-up -Drivers and Emerging Opportunities
มุมมอง 273ปีที่แล้ว
Start Up 2 Capital Market-Wealth Multiplier -2 Session1-Start-up -Drivers and Emerging Opportunities
VIPCA Foundation day celebration 23rd September 2022
มุมมอง 982 ปีที่แล้ว
VIPCA Foundation day celebration 23rd September 2022
VIPCA 14th Annual Conference 2022 - By Dr Girish Ahuja on Various Critical Issues of Income Tax
มุมมอง 2.8K2 ปีที่แล้ว
VIPCA 14th Annual Conference 2022 - By Dr Girish Ahuja on Various Critical Issues of Income Tax
VIPCA 14th Annual Conference 2022 - Session on Capital Markets by NSE
มุมมอง 1552 ปีที่แล้ว
VIPCA 14th Annual Conference 2022 - Session on Capital Markets by NSE
VIPCA 14th Annual Conference 2022 - Session on Capital Markets
มุมมอง 9K2 ปีที่แล้ว
VIPCA 14th Annual Conference 2022 - Session on Capital Markets

ความคิดเห็น

  • @rgrking
    @rgrking วันที่ผ่านมา

    Thankyou for this great . Can we please get the excel file? Thanks

  • @jatannaskar9355
    @jatannaskar9355 หลายเดือนก่อน

    If reinvest the total amount in same year than what will ta?

  • @RaviShankarGoyal
    @RaviShankarGoyal 3 หลายเดือนก่อน

    Thanks for your wonderful presentation and knowledge

  • @uma11977
    @uma11977 3 หลายเดือนก่อน

    thanks. Very informative.

  • @kushalchowdhary4279
    @kushalchowdhary4279 9 หลายเดือนก่อน

    Can you share the PPT

  • @amarnathsingla1224
    @amarnathsingla1224 11 หลายเดือนก่อน

    Book profit means stop profit ?😊

  • @amarnathsingla1224
    @amarnathsingla1224 11 หลายเดือนก่อน

    Stop loss means book loss

  • @niket002
    @niket002 11 หลายเดือนก่อน

    Thankyou for this great video. Can we please get the excel file? Thanks

  • @alihassan-bv3ph
    @alihassan-bv3ph ปีที่แล้ว

    Sir can you share a practice file

  • @roxyroxy7671
    @roxyroxy7671 ปีที่แล้ว

    छtalking with fund mangers will result u as fund mangers.....

  • @heenazaveri9632
    @heenazaveri9632 ปีที่แล้ว

    good evening, i want this templet sheet

  • @DevendraKumar-ob6hd
    @DevendraKumar-ob6hd ปีที่แล้ว

    Dear sir Financial statements read kar lijiye ca log to VIP road ca par chartered accountant log kab se wrong investment idea dene lage retail investors ko. good advise nhi dene aata to wrong advise nahi dijiye kisi ko.

  • @renganseshadri
    @renganseshadri ปีที่แล้ว

    When I select quiery to be closed and loaded, closing balance for all rows are blank

  • @akashbiradar2712
    @akashbiradar2712 ปีที่แล้ว

    5:00

  • @KundanKumar-kk2wk
    @KundanKumar-kk2wk ปีที่แล้ว

    Sir aaplog ase program kar Kay hum jse samnya logo pay bhut meharbani kartay hai 🙏

  • @arnabbhattacharya6579
    @arnabbhattacharya6579 ปีที่แล้ว

    Actual thing start around 8.30 minutes

  • @divanshkondinya
    @divanshkondinya ปีที่แล้ว

    how bonus shares will be taxed after conversion into LLP, If LLP is dissolving

  • @shivagore9313
    @shivagore9313 2 ปีที่แล้ว

    Important Part Starts at 05.00

  • @kansingh5968
    @kansingh5968 2 ปีที่แล้ว

    Nice

  • @biganna99
    @biganna99 2 ปีที่แล้ว

    AY 2013-14/14-15 cases will fall within the 10 year criterion and hence they shall be reassessed... See that. ITD has yet to interpret this judgement in it's own way..

  • @milindbidve8250
    @milindbidve8250 2 ปีที่แล้ว

    Piyush sir you are the best

  • @siddhucool2003
    @siddhucool2003 2 ปีที่แล้ว

    छा गये सर जी

  • @milindbidve8250
    @milindbidve8250 2 ปีที่แล้ว

    Superb guidence piyush sir

  • @MostafizurRahman-bv5eu
    @MostafizurRahman-bv5eu 2 ปีที่แล้ว

    Can I get Kapil Sir's contact details

  • @vinayshah1042
    @vinayshah1042 3 ปีที่แล้ว

    Virendar Bansal grilled the panelist very well. LOL

  • @vinayshah1042
    @vinayshah1042 3 ปีที่แล้ว

    I would like to thank VIP Road Chartered Accountants study circle for bringing Mr. Piyush Patel in the panel. One of the best guru/teacher/analyst. His knowledge is deep and excellent. He guided many newbies like me and many others. The way he explained concepts in very simple language so anyone can understand.

  • @meditationandhealingmusic5684
    @meditationandhealingmusic5684 3 ปีที่แล้ว

    If some prosecution pending against company under income tax act then conversion possible pvt ltd into llp

  • @ashaagarwal4183
    @ashaagarwal4183 3 ปีที่แล้ว

    COMPLEX LAW OF GST EXPLAINED IN A SIMPLE WAY.

  • @ramakantasopa3921
    @ramakantasopa3921 3 ปีที่แล้ว

    Can I get Kapil Sir drafted 3nos. pdf reply?

  • @vivekmalik6714
    @vivekmalik6714 3 ปีที่แล้ว

    Can we talk

  • @gulamjilani6945
    @gulamjilani6945 3 ปีที่แล้ว

    Old site ko hi resume kr do please 🙏 Tumse na ho payega- new incometax website

  • @h4hiten
    @h4hiten 3 ปีที่แล้ว

    6:32 Residential status

  • @dedetarrah144
    @dedetarrah144 3 ปีที่แล้ว

    0:41 vow.fyi

  • @manireddy869
    @manireddy869 3 ปีที่แล้ว

    Please share the excel file

  • @aakashsharma9218
    @aakashsharma9218 3 ปีที่แล้ว

    From where i can get the Excel Sheet???

  • @cakbhalotia
    @cakbhalotia 3 ปีที่แล้ว

    I feel speaker had a good but unstructured content. Deliberation in hinglish would have been more effective. Not criticism but constructive feedback.

  • @deepakchutani5967
    @deepakchutani5967 3 ปีที่แล้ว

    Excellent sir.. you are a young Chartered Accountant

  • @mohitpathak1416
    @mohitpathak1416 3 ปีที่แล้ว

    Limit of RS.10,000.00 is applicable on purchasing of capital asset of charitable trust or not.

  • @meghashivakumar1560
    @meghashivakumar1560 3 ปีที่แล้ว

    Yes waiting for the Excel sheets shown by premnath sir!

  • @mangalahampasagar
    @mangalahampasagar 3 ปีที่แล้ว

    Please share link to download excel sheet provided by Premanath sir

  • @tianadsouza1164
    @tianadsouza1164 3 ปีที่แล้ว

    Very useful sessions

  • @shoaib8861
    @shoaib8861 3 ปีที่แล้ว

    I want to extract data in format of opening bal, Debit,credit,closing balance.I got the opening field in ODBC but could not found debit and credit can some body please help me

  • @ashishmishra6972
    @ashishmishra6972 3 ปีที่แล้ว

    Pls mam, share the excel sheet

  • @omnamahshivay970
    @omnamahshivay970 4 ปีที่แล้ว

    @4:48 NRI thing

  • @caorugantisridhar3169
    @caorugantisridhar3169 4 ปีที่แล้ว

    Good initiative sir, thank you

  • @studyiqchannel3520
    @studyiqchannel3520 4 ปีที่แล้ว

    I am a lawyer and I had the very same opinion.I have a suggestion to all my dear law students: The more you study law bare acts,the more u will get confused so directly jump into practise and learn only what is requred in practise.

  • @lahaa53
    @lahaa53 4 ปีที่แล้ว

    COVID19 and Ivermectin High population density plus unlocking lead to community transmission, resulting in fast increase in the number of COVID19 cases in India. Good news is that, large number of infected persons would be cured of the disease without much symptoms; these asymptomatic persons would not subject themselves to any form of testing or treatment; they would roam freely in society and would infect more persons - and this would usher in HERD IMMUNITY in India. Patients with mild-to-moderate symptoms do not require costly indoor treatment; and such patients should be treated by doctors at the periphery; and the doctors should treat these patients based on clinical assessments of the patients - elaborate testing, to exclude COVID19, for each and every persons suffering from fever with mild-to-moderate Flu-like symptoms is a very costly proposition. There would be severe forms of chaos if we try to cater indoor treatment to all symptomatic patients presenting with mild-to-moderate Flu-like features. However, severely ill patients, aged patients with comorbidities should be admitted in well-equipped institutions. ICMR should allow doctors, not attached to any state-run hospital or private institution, to treat patients with mild-to-moderate Flu-like symptoms with a cocktail of drugs - Vitamin D, Vitamin C, Zinc, Azithromycin and Ivermectin. Doctors attached to state-run or private institutions are, I think, already instructed by ICMR about management of such patients at indoor and outdoor. COVID19 is a Global emergency; we do not have much time for elaborate clinical trials (multi-centric, double-blind, placebo-controlled, above all, reports should be acceptable to peer-group-reviewed international Journals) to prove or disprove efficacy of Ivermectin in treating COVID19. Doctors of many nations have published reports proving excellent efficacy of Ivermectin; no doubt, these studies have been conducted with a small number of patients; but still, we cannot discard the inferences of these reports out right, because these findings are collected by senior physicians with long experiences in clinical medicine. Arun Kumar Laha 09 06 2020 < laha.a53@gmail.com > IVERMECTIN Times Of India published two reports on 21st and 22th May praising Rendesivir and Favipiravir, two antivirals. Mainstream media worldwide are promoting these drugs of big pharma companies; however, most, if not all, antivirals are of questionable efficacy. No one is promoting IVERMECTIN, a cheap oral drug, prescribing which against COVID19 doctors from many nations, including Bangladesh, got EXCELLENT results. No one is interested in promoting this off patented molecule. Scientists could not fabricate vaccines against all and every pathogenic Virus; most probably, COVID19 is one of such type. Monoclonal antibody against viral proteins, however, is a good treatment plan. NO MASK, NO SOCIAL DISTANCING, NO LOCKDOWN, WILL BE ABLE TO SAVE HUMANITY FROM COVID19. IVERMECTIN, HCQ AND HERD IMMUNITY DUE TO SUBCLINICAL INFECTION IN COMMUNITY AT LARGE WOULD SAVE US. Fight against COVID19 To fight against COVID19 India has to chalk out her own plan; we should not ape other nations. There would be serious socio-economic disaster in India if we continue total or partial lockdown. Most of the COVID19 infected patients in India are asymptomatic; and this might be due to the presence of Curcumin in our daily food. So, it is very difficult to determine patient- load in India; we can not test for COVID19 in all persons under the Sun. Asymptomatic persons would refuse testing and any form of treatment - they would roam freely in society; and would infect the population at large; and this will in near future usher in HERD IMMUNITY in India. Most of the symptomatic patients present with mild to moderate illness; we should treat them as OPD patients. We have to treat these patients with mild-to-moderate Flu-like symptoms as quickly as possible; so that they do not become severely ill to overwhelm the scarce indoor facilities in our country. Here is a safe outdoor treatment plan that will show quick and effective response in symptomatic patients (for adults): - Vitamin D & C and Zinc daily in usual recommended doses + Virostatic drug Ivermectin 12mg daily for 3 to 5 days + Senolytic antibiotic Azithromycin 250mg to 500mg daily for 5 days to 10 days. This treatment plan ushers in prompt response. Serious indoor patients would get these medicines + necessary supportive measures + Hydroxychloroquine (HCQS). - Arun Kumar Laha 29, Abinash Banerjee Lane. Howrah 711104. (laha.a53@gmail.com) Disclaimer: - This is not a prescription for the general public to self- medicate themselves. It is for the medical fraternity to think about my humble suggestion. To solve the problems of COVID 19, lockdown is not the only way out; we have to rely on development of HERD IMMUNITY by exposing people to low grade infection with COVID19 and we have to treat the symptomatic patients as fast as possible, to cut short the number of serious patients requiring indoor treatment. Many health- care personnel and other fighters against COVID19 are losing their lives to save humanity at large; ICMR should think about prescribing IVERMECTIN (12mg in empty stomach once in a week instead of Hydroxychloroquine) to these persons. Ivermectin is safer than Hydroxychloroquine.

  • @Ashishsh1980
    @Ashishsh1980 4 ปีที่แล้ว

    Plz share link for income tax changes 20-21 & capital Gain

  • @Ashishsh1980
    @Ashishsh1980 4 ปีที่แล้ว

    Nice sirji

  • @taxationtalk8049
    @taxationtalk8049 4 ปีที่แล้ว

    Girish Ahuja sir is the ocean of knowledge #taxationtalk